Perspective Therapeutics Inc.
Organization details
- Legal name
- Perspective Therapeutics Inc.
- Former names
- IsoRay, Inc. Century Park Pictures Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CATX
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0000728387
- EIN
- 41-1458152
Board of directors
-
Frank Morich · DirectorSince 2023
-
Heidi Henson · DirectorSince 2023
-
Johan M. Spoor · Director · Chief Executive OfficerSince 2023
-
Lori A. Woods · DirectorSince 2023
-
Maria E. Martinez · DirectorSince 2025
-
Michael W. McCormick · DirectorSince 2023
-
Robert F. Williamson III · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 27, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.6%
-
87.9%
-
90.1%
-
96.1%
Board connections
2 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
Cue Biopharma Inc. Same sectorvia Frank Morich
-
Korsana Biosciences Inc. Same sectorvia Heidi Henson
-
Lisata Therapeutics Inc. Same sectorvia Heidi Henson
-
PepGen Inc. Same sectorvia Heidi Henson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $42,276
- 2 purchases by 2 insiders
- Sold, last 12 months
- $1,622,725
- 7 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | Lantheus Alpha Therapy, LLC 10% owner | Open-market sale | −167,149 | $3.15 | $526,519 |
| Sep 3, 2026 | Lantheus Alpha Therapy, LLC 10% owner | Open-market sale | −80,783 | $3.11 | $251,235 |
| Sep 2, 2026 | Lantheus Holdings, Inc. 10% owner | Open-market sale | −42,129 | $3.11 | $131,021 |
| Sep 1, 2026 | Lantheus Holdings, Inc. 10% owner | Open-market sale | −35,769 | $3.12 | $111,599 |
| Sep 1, 2026 | Lantheus Alpha Therapy, LLC 10% owner | Open-market sale | −35,769 | $3.12 | $111,599 |
| Aug 31, 2026 | Lantheus Holdings, Inc. 10% owner | Open-market sale | −78,145 | $3.14 | $245,375 |
| Aug 31, 2026 | Lantheus Alpha Therapy, LLC 10% owner | Open-market sale | −78,145 | $3.14 | $245,375 |
| Nov 13, 2025 | Hunt Jonathan Robert Officer (Chief Accounting Officer) | Open-market purchase | +11,000 | $2.03 | $22,330 |
| Nov 12, 2025 | Robert F. Williamson III Director | Open-market purchase | +9,498 | $2.10 | $19,946 |
| Mar 31, 2025 | Lori A. Woods Director | Open-market purchase | +23,475 | $2.13 | $50,002 |
| Mar 31, 2025 | Robert F. Williamson III Director | Open-market purchase | +38,145 | $2.14 | $81,630 |
| Mar 28, 2025 | Johan M. Spoor Director, Officer (Chief Executive Officer) | Open-market purchase | +22,026 | $2.24 | $49,338 |
| Mar 28, 2025 | Robert F. Williamson III Director | Open-market purchase | +22,192 | $2.27 | $50,376 |
| Mar 28, 2025 | Graham Juan Officer (Chief Financial Officer) | Open-market purchase | +33,333 | $2.25 | $74,999 |
| Mar 28, 2025 | Johan M. Spoor Director, Officer (Chief Executive Officer) | Open-market purchase | +4,650 | $2.21 | $10,277 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Perspective Therapeutics Inc.
Who is the CEO of Perspective Therapeutics Inc.?
Johan M. Spoor has been Perspective Therapeutics Inc.'s CEO since February 2023.
How many directors are on Perspective Therapeutics Inc.'s board?
Perspective Therapeutics Inc.'s board has 7 directors: Frank Morich, Heidi Henson, Johan M. Spoor, Lori A. Woods, Maria E. Martinez, Michael W. McCormick and Robert F. Williamson III.
Are Perspective Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Perspective Therapeutics Inc. insiders bought $42,276 of shares in 2 purchases and sold $1.6 million of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="perspective-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.